304am永利集团|·主頁(歡迎您)

Be the most trusted biotech company

2021-11-08

Henlius Announces Successful Completion of Phase 1 Clinical Trial of Pertuzumab Biosimilar HLX11
2021-10-13

First Subject Dosed in Phase 1 Clinical Trial of Henlius’ Novel Anti-LAG-3 mAb HLX26
2021-10-12

Henlius Announces Dr. Jean-Michel Gries as President of Hengenix
2021-09-30

First Patient Dosed in Phase 2 Clinical Trial of HLX22 Combo Therapy in Patients with HER2-positive Gastric Cancer
2021-09-28

Hepatocellular Carcinoma Phase 2 Clinical Study Results of a Novel anti-PD-1 mAb Serplulimab has been Selected for the Innovation Session at 2021 CSCO
2021-09-26

Henlius Presents Results from Phase 2 Clinical Study of Its Novel anti-PD-1 mAb Serplulimab in Patients with Advanced Cervical Cancer at 2021 CSCO
2021-09-26

Henlius Presents Results from Phase 3 Clinical Study of HLX04 (Bevacizumab Biosimilar) in Patients with Metastatic Colorectal Cancer at 2021 CSCO
2021-09-26

Henlius Presents Results from Phase 2 Study of Its Novel anti-PD-1 mAb Serplulimab in Patients with MSI-H or Mismatch Repair-deficient Solid Tumours at 2021 CSCO
2021-09-18

Henlius will Release 4 Oral Presentations of 2 Upcoming Commercial Products: Novel anti-PD-1 mAb Serplulimab and Bevacizumab Biosimilar HLX04

1
2
3
4
5